Luca Antonelli, Davide Ardizzone, Isamu Tachibana, Nabil Adra, Clint Cary, Lee Hugar, Wade J Sexton, Aditya Bagrodia, Michal Mego, Siamak Daneshmand, Nicola Nicolai, Sebastiano Nazzani, Patrizia Giannatempo, Andrea Franza, Axel Heidenreich, Pia Paffenholz, Ragheed Saoud, Scott Eggener, Matthew Ho, Nathaniel Oswald, Kathleen Olson, Alexey Tryakin, Mikhail Fedyanin, Natacha Naoun, Christophe Javaud, Walter Cazzaniga, David Nicol, Axel Gerdtsson, Torgrim Tandstad, Karim Fizazi, Christian Daniel Fankhauser
PURPOSE: No consensus exists on the management of men with nonseminoma and viable nonteratomatous germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection (pcRPLND) specimen after first-line chemotherapy. We analyzed surveillance versus different adjuvant chemotherapy regimens and the influence of time to pcRPLND on oncologic outcomes. METHODS: Data on 117 men treated with cisplatin-based first-line chemotherapy between 1990 and 2018 were collected from 13 institutions...
December 1, 2023: Journal of Clinical Oncology